Correction to: Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

Hans-Peter Hartung^{1,2,3,4} · Jan Mares³ · Sven G. Meuth¹ · Thomas Berger⁴

Published online: 2 November 2021

© The American Society for Experimental NeuroTherapeutics, Inc. 2021

Correction to: Neurotherapeutics (2021)

<https://doi.org/10.1007/s13311-021-01102-w>

This correction is to update the wording “In this issue” in the opening sentence of paragraph #2 referring to reference 23, which was published in Volume 18, Issue 2. This line has been corrected to “As published in the April 2021 issue.”

The original article had been corrected.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s13311-021-01102-w>.

✉ Hans-Peter Hartung
hans-peter.hartung@uni-duesseldorf.de

¹ Department of Neurology, Heinrich-Heine-University
Düsseldorf, Düsseldorf, Germany

² Brain and Mind Centre, University of Sydney, Sydney,
Australia

³ Department of Neurology, Palacky University Olomouc,
Olomouc, Czech Republic

⁴ Department of Neurology, Medical University of Vienna,
Vienna, Austria